LENSAR (NASDAQ:LNSR) Upgraded by Wall Street Zen to Hold Rating

LENSAR (NASDAQ:LNSR) was upgraded by Wall Street Zen to a “hold” rating in a research report issued on Friday.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of LENSAR in a research note on Wednesday, October 8th. Two equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Reduce” and an average price target of $15.00.

LENSAR Stock Performance

Shares of NASDAQ:LNSR opened at $10.17 on Friday. The company’s fifty day moving average is $11.48 and its 200-day moving average is $12.41. LENSAR has a 52 week low of $7.13 and a 52 week high of $17.31. The company has a market capitalization of $121.43 million, a PE ratio of -2.32 and a beta of 0.49.

LENSAR (NASDAQ:LNSR) last announced its earnings results on Thursday, November 6th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.23). The firm had revenue of $14.32 million for the quarter, compared to analyst estimates of $17.75 million. LENSAR had a negative return on equity of 737.30% and a negative net margin of 87.12%.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of LNSR. Groupe la Francaise acquired a new stake in shares of LENSAR in the 1st quarter valued at $1,779,000. OMERS ADMINISTRATION Corp acquired a new position in shares of LENSAR during the first quarter valued at $1,680,000. Geode Capital Management LLC boosted its holdings in LENSAR by 103.9% in the second quarter. Geode Capital Management LLC now owns 219,373 shares of the company’s stock valued at $2,890,000 after acquiring an additional 111,802 shares during the last quarter. Credit Industriel ET Commercial increased its position in LENSAR by 98.4% in the second quarter. Credit Industriel ET Commercial now owns 168,600 shares of the company’s stock worth $2,220,000 after purchasing an additional 83,600 shares during the period. Finally, Skandinaviska Enskilda Banken AB publ bought a new stake in LENSAR during the 2nd quarter worth about $756,000. 40.15% of the stock is currently owned by institutional investors.

About LENSAR

LENSAR, Inc, a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision.